Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tc 99m nofetumomab merpentan

Drug Profile

Tc 99m nofetumomab merpentan

Alternative Names: F(ab)2 NRLU10 technetium (Tc 99m); OncoTrac; OncoTrac NSCLC; OncoTrac SCLC; Technetium Tc 99m-nofetumomab merpentan; VerLuma

Latest Information Update: 21 Jun 2006

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Poniard Pharmaceuticals
  • Class Monoclonal antibodies; Monoclonal antibody diagnostics; Organotechnetium compounds; Radiopharmaceuticals; Technetium compounds
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Non-small cell lung cancer; Small cell lung cancer

Most Recent Events

  • 21 Jun 2006 NeoRx Corporation is now called Poniard Pharmaceuticals Inc.
  • 22 May 1997 Launched for Small cell and Non-small cell lung cancer diagnosis in USA (IV)
  • 12 Feb 1997 Registered for Small cell and Non-small cell lung cancer diagnosis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top